Methods of detecting cell-free dna in biological samples

Abstract

The present disclosure is directed to methods of detecting cell-free DNA (cfDNA) in biological samples and using it to quantify organ damage and identify pathogens. In some aspects, the biological samples are from patients who have undergone solid-organ transplantation. The disclosure is also directed to methods of detecting and analyzing methylation patterns in cell-free DNA from organ transplant patients to identify the presence of pathogens as well as quantify contributing tissue proportions as a measurement of the host response.

1 .- 21 . (canceled) 
     
     
         22 . A method comprising:
 (a) subjecting cell-free DNA (cfDNA) isolated from a sample from a human host subject to bisulfite treatment;   (b) preparing a single-stranded sequencing library of the bisulfite treated cfDNA;   (c) obtaining the sequences of the cfDNA in the sequencing library; and   (d) identifying host DNA sequences by aligning the sequences from step (c) to human reference genome and identifying and removing sequences that align to the human reference genome, wherein the remaining sequences are the non-host DNA sequences;   (e) identifying non-host DNA sequences by aligning the non-host DNA sequences to a database of reference genomes to identify the non-host DNA sequences;   (f) obtaining the methylation profile of the cfDNA based on the sequences obtained in step (c); and   (g) determining the tissue of origin of the host DNA based on the methylation profile of the host DNA.   
     
     
         23 . A method comprising:
 (a) subjecting cell-free DNA (cfDNA) isolated from a sample from a human host subject suspected of having an infection to bisulfite treatment;   (b) preparing a single-stranded sequencing library of the bisulfite treated cfDNA;   (c) obtaining the sequences of the cfDNA in the sequencing library; and   (d) identifying host DNA sequences by aligning the sequences from step (c) to human reference genome and identifying and removing sequences that align to the human reference genome, wherein the remaining sequences are the non-human DNA sequences;   (e) identifying non-human DNA sequences by aligning the non-host DNA sequences to a database of non-human reference genomes to identify the non-human DNA sequences;   (f) obtaining the methylation profile of the cfDNA based on the sequences obtained in step (c); and   (g) determining the tissue of origin of the host DNA based on the methylation profile of the host DNA.   
     
     
         24 . The method of  claim 22 , wherein the non-host DNA is a non-human DNA. 
     
     
         25 . The method of  claim 22 , wherein the DNA molecules in the sequencing library vary between 25 to 350 bp in length. 
     
     
         26 . The method of  claim 22 , wherein the non-host DNA is a microbial DNA. 
     
     
         27 . The method of  claim 26 , further comprising determining the source of the microbial DNA by aligning the sequences of the microbial DNA to a database of microbial reference genomes. 
     
     
         28 . The method of  claim 22 , further determining that the subject is undergoing an infection if an increased number of microbial sequences is detected from the sample, compared to a sample of a healthy control. 
     
     
         29 . The method of  claim 22 , wherein the determining the tissue of origin comprises aligning the methylation profile of the sequences of the host DNA to a methylation reference panel. 
     
     
         30 . The method of  claim 22 , wherein the subject is a kidney transplant recipient and the non-host DNA is donor DNA in the cfDNA sample. 
     
     
         31 . The method of  claim 30 , wherein the detection of donor DNA is achieved by the steps comprising:
 (i) aligning the DNA sequences from step (c) to a human reference genome; and   (ii) identifying donor DNA from single nucleotide polymorphisms (SNPs) in the sequences that align to the human reference genome that differ from the SNPs in the host genome, wherein is host genome SNP information is derived from a pre-transplant whole blood sample of the subject.   
     
     
         32 . The method of  claim 31 , further comprising determining the fraction of donor DNA based on the SNP information. 
     
     
         33 . The method of  claim 30 , wherein the donor and the recipient are of different sexes and the detection of donor DNA is achieved by the steps comprising:
 (i) aligning the DNA sequences from step (c) to a human reference genome; and   (ii) determining fraction of the donor DNA by the ratio of the coverage of the Y chromosome and the coverage of an autosome.   
     
     
         34 . The method of  claim 33 , wherein the donor is a female and the recipient is a male, it is determined that there is donor DNA in the sample if the ratio of chromosome Y coverage to that of the autosome is less than 0.5; it is determined that all the cfDNA in the sample is donor DNA if the ratio of chromosome Y coverage to that of any autosome is zero; and it is determined that there is no donor DNA in the sample if the ratio of chromosome Y coverage to that of any autosome is exactly 0.5. 
     
     
         35 . The method of  claim 33 , wherein the donor is a male and the recipient is a female, and it is determined that there is donor DNA in the sample any DNA sequences align to chromosome Y; it is determined that all the cfDNA in the sample is donor DNA if the ratio of chromosome Y coverage to that of any autosome is exactly and it is determined that there is no donor DNA in the sample if the ratio of chromosome Y coverage to that of any autosome is exactly zero. 
     
     
         36 . The method of  claim 28 , wherein the method further comprises quantifying the proportion of host DNA from a tissue as a measurement of damage to said tissue resulting from the infection. 
     
     
         37 . The method of  claim 23 , wherein the DNA molecules in the sequencing library vary between 25 to 350 bp in length. 
     
     
         38 . The method of  claim 23 , wherein the non-human DNA is a microbial DNA. 
     
     
         39 . The method of  claim 38 , further comprising determining the source of the microbial DNA by aligning the sequences of the microbial DNA to a database of microbial reference genomes. 
     
     
         40 . The method of  claim 23 , wherein the subject is undergoing an infection if an increased number of microbial sequences is detected from the sample, compared to a sample of a healthy control. 
     
     
         41 . The method of  claim 23 , wherein the determining the tissue of origin comprises aligning the methylation profile of the sequences of the host DNA to a methylation reference panel. 
     
     
         42 . The method of  claim 23 , wherein the method further comprises quantifying the proportion of host DNA from a tissue as a measurement of damage to said tissue resulting from the infection.